Real-World Treatment Patterns and Clinical Outcomes Among Patients with Metastatic Castration-resistant Prostate Cancer (mCRPC): An Emerging Market Medical Record Review Study - NI

Pfizer Limited0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年8月19日

试验速览

暂无简介。

•1. New diagnosis of mCRPC during the case selection window (between 15 April 2019 to 14 January 2022, inclusive). mCRPC is defined as the current and/or historical presence of metastases on any imaging modality with evidence of disease progression (a rising PSA or radiographic progression (as defined by the investigator) despite ongoing castration therapy [LHRH agonist / antagonist or prior surgical
•orchiectomy]).
•2. Aged at least 18 years upon diagnosis of mCRPC.
•Of note, patients may be alive or deceased at the date of data abstraction.

•Previously enrolled in an interventional trial related to CRPC (patients may have been
•enrolled in trials of primary treatment and/or hormone-sensitive prostate cancer).

发起方